However, the combined treatment of HCC cells with 1 μM sorafenib and the HDAC inhibitor SAHA significantly enhanced LDH release into the supernatant as compared with treatment using the same SAHA or sorafenib doses alone (Figure 7B; Figure S4B). Here, HDAC9 is linked to hepatocellular carcinoma.